NCT04740580 · Early Phase 1 · RECRUITING
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
This trial is testing whether two dietary supplements, glycine and N-acetylcysteine (together called GlyNAC), can improve brain metabolism, reduce inflammation, and help cognition in people with Alzheimer's disease. Participants are compared against a placebo group taking alanine. It is an early Phase 1 trial, meaning researchers are still in the earliest stage of testing safety and early signals of effect in humans — this is not a proven treatment.
You may qualify if
- Age 55-85 years;
- Gradual and progressive memory loss for more than 1 year, with a Montreal Cognitive Assessment score of 10-20;
- Amyloid positivity on PET scan;
- Availability of a study partner.
You're excluded if
- hospitalization in past 3 months;
- use of insulin medications;
- untreated thyroid disease;
- creatinine levels >1.5 mg/dL;
- hemoglobin concentration \<11.0 g/dL;
- known liver disease, or AST/ALT level >2x ULN;
- history of stroke, brain tumor, active heart failure or active cancer (removable basal cell cancers will not be an exclusion criteria);
- untreated depression or other severe psychiatric disorders;
- pregnancy or nursing (unlikely in this population)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-06-10